MCID: THR004
MIFTS: 51

Thrombocytosis

Categories: Blood diseases

Aliases & Classifications for Thrombocytosis

MalaCards integrated aliases for Thrombocytosis:

Name: Thrombocytosis 12 74 29 54 43 15 71
Thrombocythaemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2228
MeSH 43 D013922
NCIt 49 C35530
SNOMED-CT 67 6631009
UMLS 71 C0836924

Summaries for Thrombocytosis

Disease Ontology : 12 A blood platelet disease that is characterized by the presence of high platelet counts in the blood.

MalaCards based summary : Thrombocytosis, also known as thrombocythaemia, is related to myelodysplastic/myeloproliferative neoplasm and temporal arteritis. An important gene associated with Thrombocytosis is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are hematopoietic system and cardiovascular system

Wikipedia : 74 Thrombocythemia is a condition of high platelet (thrombocyte) count in the blood. Normal count is in the... more...

Related Diseases for Thrombocytosis

Diseases related to Thrombocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 784)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic/myeloproliferative neoplasm 33.1 TET2 JAK2 CSF2
2 temporal arteritis 32.9 IL6 IL1B CRP
3 transient erythroblastopenia of childhood 32.5 KITLG EPO
4 splenomegaly 31.5 MPL JAK2 EPO
5 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 31.5 IL3 EPO CSF3 CRP
6 iron deficiency anemia 31.3 THPO IL6 EPO CRP
7 refractory anemia 31.3 TET2 MPL IL3 EPO CSF3
8 polycythemia vera 31.3 THPO TET2 SELP MPL KITLG JAK2
9 essential thrombocythemia 31.0 THPO TET2 SERPINC1 SELP PPBP MPL
10 thrombophilia due to thrombin defect 31.0 SERPINC1 F3 F2
11 paraneoplastic syndromes 31.0 IL6 CSF3
12 blood platelet disease 31.0 THPO SERPINC1 SELP MPL JAK2 IL6
13 myeloid leukemia 30.8 TET2 LIF JAK2 IL3 CSF3 CSF2
14 granulocytopenia 30.8 IL3 CSF3 CSF2
15 leukemia 30.7 THPO TET2 MPL LIF JAK2 CSF2
16 osteomyelitis 30.7 IL6 IL1B CSF3
17 eosinophilic pneumonia 30.7 IL6 IL3 CSF2
18 erythrocytosis, familial, 1 30.6 JAK2 IL3 EPO
19 portal hypertension 30.6 THPO JAK2 F3 F2
20 bronchiolitis 30.6 IL6 IL11 CRP
21 syphilis 30.6 IL6 F2 CRP
22 thrombocytopenic purpura, autoimmune 30.5 THPO SELP MPL IL11
23 intracranial hypertension 30.5 SERPINC1 IL1B F3 F2
24 pulmonary embolism 30.5 SERPINC1 F3 F2 CRP
25 acute cystitis 30.5 IL6 IL1B F2 CRP
26 amegakaryocytic thrombocytopenia, congenital 30.5 THPO MPL JAK2 IL3
27 pyuria 30.5 IL6 F2 CRP
28 thrombocytopenia due to platelet alloimmunization 30.5 THPO SELP MPL
29 budd-chiari syndrome 30.4 SERPINC1 MPL JAK2 F3 F2
30 heparin-induced thrombocytopenia 30.4 SERPINC1 F3
31 bacterial meningitis 30.4 IL6 IL1B CSF2 CRP
32 beta-thalassemia 30.4 SERPINC1 JAK2 IL3 F2 EPO
33 thrombophilia due to activated protein c resistance 30.4 SERPINC1 F3 F2
34 lateral sinus thrombosis 30.4 SERPINC1 F3 F2
35 deficiency anemia 30.4 THPO SERPINC1 SELP LIF JAK2 IL6
36 sagittal sinus thrombosis 30.4 SERPINC1 F3 F2
37 angina pectoris 30.4 IL6 F3 CRP
38 hemolytic anemia 30.4 IL3 F3 F2 EPO CSF3
39 active peptic ulcer disease 30.4 F3 F2 CRP
40 poems syndrome 30.4 IL6 IL1B EPO CSF3
41 portal vein thrombosis 30.4 SERPINC1 SELP MPL JAK2 F2 CRP
42 polyarteritis nodosa 30.4 SELP IL6 CRP
43 iritis 30.3 IL6 EPO CRP
44 purpura 30.3 THPO SERPINC1 MPL IL6 F3 F2
45 spinal cord infarction 30.3 SERPINC1 F2
46 acute monoblastic leukemia 30.3 IL6 EPO CSF2
47 nonarteritic anterior ischemic optic neuropathy 30.3 SERPINC1 F2 CRP
48 vitamin k deficiency bleeding 30.3 SERPINC1 F3 F2
49 vaginal discharge 30.3 IL6 IL1B CRP
50 erysipelas 30.3 IL6 IL1B CRP

Graphical network of the top 20 diseases related to Thrombocytosis:



Diseases related to Thrombocytosis

Symptoms & Phenotypes for Thrombocytosis

MGI Mouse Phenotypes related to Thrombocytosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CD177 CSF2 CSF3 EPO F2 F3
2 cardiovascular system MP:0005385 10.29 CRP CSF2 EPO F2 F3 IL1B
3 immune system MP:0005387 10.25 CD177 CRP CSF2 CSF3 EPO F2
4 homeostasis/metabolism MP:0005376 10.21 CRP CSF2 EPO F2 F3 IL1B
5 cellular MP:0005384 10.2 CSF2 EPO F2 F3 IL6 JAK2
6 embryo MP:0005380 10.09 CSF2 EPO F2 F3 JAK2 KITLG
7 integument MP:0010771 10 CSF2 CSF3 EPO F2 F3 IL1B
8 liver/biliary system MP:0005370 9.76 EPO IL6 JAK2 KITLG LIF SELP
9 neoplasm MP:0002006 9.5 CSF2 F3 IL1B IL6 JAK2 KITLG
10 respiratory system MP:0005388 9.23 CSF2 EPO F2 F3 IL6 JAK2

Drugs & Therapeutics for Thrombocytosis

Drugs for Thrombocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Panobinostat Approved, Investigational Phase 4 404950-80-7 6918837
4
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
5 Histone Deacetylase Inhibitors Phase 4
6
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
7
Sodium citrate Approved, Investigational Phase 3 68-04-2
8
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
9
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
10
Anagrelide Approved Phase 3 68475-42-3 2182
11
Hydroxyurea Approved Phase 3 127-07-1 3657
12
Mercaptopurine Approved Phase 3 50-44-2 667490
13
Danazol Approved Phase 3 17230-88-5 28417
14
Melphalan Approved Phase 3 148-82-3 460612 4053
15
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
16
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
17 Analgesics, Non-Narcotic Phase 3
18 Analgesics Phase 3
19 Anti-Inflammatory Agents Phase 3
20 Cyclooxygenase Inhibitors Phase 3
21 Antirheumatic Agents Phase 3
22 Antipyretics Phase 3
23 Anti-Inflammatory Agents, Non-Steroidal Phase 3
24 Mitogens Phase 3
25 Androgens Phase 3
26 Protein Kinase Inhibitors Phase 3
27 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
28 Hormones Phase 3
29 Hormone Antagonists Phase 3
30 Estrogen Antagonists Phase 3
31 Estrogen Receptor Antagonists Phase 3
32 Hepcidins Phase 3
33 Estrogens Phase 3
34 Citrate Phase 3
35 interferons Phase 3
36 Interferon-alpha Phase 3
37 Immunologic Factors Phase 3
38 Complement System Proteins Phase 2, Phase 3
39 Antiviral Agents Phase 3
40 Anti-Infective Agents Phase 3
41 Interferon alpha-2 Phase 3
42 Fibrinolytic Agents Phase 3
43 Platelet Aggregation Inhibitors Phase 3
44 Janus Kinase Inhibitors Phase 3
45 glucocorticoids Phase 3
46
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
47
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
48
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
49
Pomalidomide Approved Phase 2 19171-19-8
50 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1

Interventional clinical trials:

(show top 50) (show all 180)
# Name Status NCT ID Phase Drugs
1 A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
2 A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients. Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
3 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
4 A Multicenter, Open-label, Clinical Study for Efficacy and Safety Evaluation of Anagrelide in Patients With Treatment-naïve, High-risk Essential Thrombocythemia as a Primary Treatment Recruiting NCT03232177 Phase 4 Anagre Cap.
5 A Prospective, Single-center Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia Recruiting NCT04226950 Phase 4 Recombinant Interferon Alpha;Pegylated interferon alfa-2b
6 Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies Recruiting NCT02386800 Phase 4 ruxolitinib tablets or oral pediatric formulation, panobinostat capsules;ruxolitinib tablets or oral pediatric formulation
7 A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia Completed NCT01065038 Phase 3 Anagrelide;Hydroxyurea
8 A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed NCT01467661 Phase 3 SPD422 (anagrelide hydrochloride)
9 A Phase 3, Open-label, Single-arm Study Evaluating the Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Who Are Intolerant or Refractory to Current Cytoreductive Treatment Completed NCT01214915 Phase 3 Anagrelide Hydrochloride
10 A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of "Anagrelide Retard" Versus Placebo in "at Risk" Subjects With Essential Thrombocythaemia Completed NCT01230775 Phase 3 Anagrelide retard;Placebo
11 A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
12 An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF). Completed NCT01493414 Phase 3 INC424
13 A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Completed NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
14 A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib Completed NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
15 A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0) Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
16 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
17 A Phase 3b, Multicenter, Single-arm, Open-label Safety AND Efficacy Study of Fedratinib in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Recruiting NCT03755518 Phase 3 FEDRATINIB
18 French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study Recruiting NCT02611973 Phase 3 Hydroxyurea treatment (HU)
19 A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib Recruiting NCT03952039 Phase 3 FEDRATINIB;Best Available Therapy (BAT)
20 A Randomized, Double-Blind, Phase 3 Study of Momelotinib vs Danazol in Symptomatic, Anemic Subjects With Previously JAKi Treated Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis Recruiting NCT04173494 Phase 3 Momelotinib;Danazol;Placebo to match momelotinib;Placebo to match danazol
21 A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA) Recruiting NCT03165734 Phase 3 Pacritinib;Physician's Choice medications
22 An Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) Active, not recruiting NCT04209634 Phase 2, Phase 3 Pozelimab
23 A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study Active, not recruiting NCT02962388 Phase 2, Phase 3 Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
24 Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms. Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
25 A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia Not yet recruiting NCT04285086 Phase 3
26 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
27 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
28 A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia. Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
29 A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Unknown status NCT01298934 Phase 1, Phase 2 LBH589
30 A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
31 A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamic and Safety Study of Anagrelide Hydrochloride in Young (18-50 Years) and Elderly (≥ 65 Years) Patients With Essential Thrombocythaemia. Completed NCT00413634 Phase 2 anagrelide hydrochloride
32 An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation Completed NCT00586651 Phase 2 lestaurtinib
33 A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Completed NCT02515630 Phase 2 MMB
34 A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN) Completed NCT02125318 Phase 2 Anagrelide CR
35 A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy Completed NCT01243073 Phase 2 Imetelstat
36 An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L Completed NCT01348490 Phase 2 Ruxolitinib
37 A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Completed NCT00745550 Phase 1, Phase 2 SB1518
38 A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis Completed NCT01392443 Phase 2 Ruxolitinib
39 Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia Completed NCT02124746 Phase 2 Momelotinib
40 A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Completed NCT01369498 Phase 2 Simtuzumab;Ruxolitinib
41 A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis Completed NCT00039416 Phase 2 imatinib mesylate
42 A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis Completed NCT01787552 Phase 1, Phase 2 LDE225;INC424
43 A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET) Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib
44 Multi-Center Phase II Study With Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Completed NCT00949364 Phase 2 Pomalidomide
45 Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT) Completed NCT00003239 Phase 2 Cytarabine;Omacetaxine Mepesuccinate
46 A Phase II Trial of R115777 in Myelofibrosis With Myeloid Metaplasia (MMM) Completed NCT00047190 Phase 2 tipifarnib
47 A Phase IIA Study of the Histone-deacetylase Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases Completed NCT00606307 Phase 2 ITF2357
48 A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01692366 Phase 2 SAR302503
49 A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia Completed NCT00227591 Phase 2 lenalidomide;prednisone
50 A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. Completed NCT02966353 Phase 2 ruxolitinib

Search NIH Clinical Center for Thrombocytosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorambucil
Uracil Mustard

Cochrane evidence based reviews: thrombocytosis

Genetic Tests for Thrombocytosis

Genetic tests related to Thrombocytosis:

# Genetic test Affiliating Genes
1 Thrombocytosis 29

Anatomical Context for Thrombocytosis

MalaCards organs/tissues related to Thrombocytosis:

40
Myeloid, Bone, Bone Marrow, Lung, Liver, Testes, Neutrophil

Publications for Thrombocytosis

Articles related to Thrombocytosis:

(show top 50) (show all 5061)
# Title Authors PMID Year
1
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. 61 54
20154217 2010
2
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. 61 54
20151976 2010
3
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. 61 54
20197548 2010
4
Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. 54 61
20194236 2010
5
JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. 61 54
19643476 2010
6
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. 54 61
19903679 2010
7
Class prediction models of thrombocytosis using genetic biomarkers. 61 54
19773543 2010
8
[Diabetes insipidus followed, after 4 years, with dysarthria and mild right-sided hemiparesis--the first clinical signs of Erdheim-Chester disease. Description and depiction of a case with a review of information on the disease]. 61 54
20070034 2009
9
[Paediatric myofibroblastic tumours. A presentation of three cases]. 54 61
19647502 2009
10
JAK2 V617F mutation and PRV-1 overexpression: relevance in the diagnosis of polycythaemia vera and essential thrombocythaemia. 61 54
19999391 2009
11
Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. 54 61
19657484 2009
12
Granulocytosis and thrombocytosis in renal cell carcinoma: a pro-inflammatory cytokine response originating in the tumour. 54 61
19581670 2009
13
Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia. 61 54
19252138 2009
14
A case of acute promyelocytic leukemia showing transient thrombocytosis caused by increased interleukin-6 and thrombopoietin after treatment with all-trans retinoic acid and chemotherapy. 61 54
19461187 2009
15
Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency. 54 61
19303685 2009
16
The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia. 54 61
19222478 2009
17
[A case of IL-6 producing malignant mesothelioma of abdomen with thrombocytosis]. 54 61
19346724 2009
18
Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. 61 54
18796624 2009
19
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. 54 61
18845793 2009
20
Mice overexpressing murine oncostatin M (OSM) exhibit changes in hematopoietic and other organs that are distinct from those of mice overexpressing human OSM or bovine OSM. 61 54
19112126 2009
21
Anagrelide: 20 years later. 61 54
19105705 2009
22
Thrombocytosis. 61 54
20008195 2009
23
General changes in hemostasis in gastric cancer. 61 54
19507648 2009
24
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation. 61 54
19174256 2009
25
Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. 61 54
19036112 2009
26
Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. 61 54
18760517 2008
27
Familial chronic myeloproliferative disorders: the state of the art. 61 54
18484677 2008
28
Incidence and clinical significance of left ventricular thrombus in tako-tsubo cardiomyopathy assessed with echocardiography. 54 61
18334499 2008
29
Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role? 61 54
18397204 2008
30
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. 54 61
18367486 2008
31
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. 61 54
18160670 2008
32
High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. 61 54
18616871 2008
33
Clinical implications of JAK2 mutations in myeloproliferative disorders. 61 54
18575049 2008
34
Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. 61 54
17688946 2008
35
Thrombopoietin levels increased in patients with severe acute respiratory syndrome. 54 61
18314161 2008
36
Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. 54 61
18041648 2007
37
Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. 61 54
17920755 2007
38
JAK2 mutations and clinical practice in myeloproliferative neoplasms. 61 54
18032973 2007
39
Neonatal thrombocytosis following G-CSF treatment. 54 61
17917868 2007
40
Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle? 54 61
18220909 2007
41
Essential versus reactive thrombocythemia in children: retrospective analyses of 12 cases. 54 61
17171694 2007
42
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation. 54 61
17285276 2007
43
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. 61 54
16820206 2007
44
[JAK2(V617F) mutation in Korean patients with essential thrombocythemia]. 61 54
18094555 2007
45
[Blood cytokine levels as a clinical laboratory test]. 61 54
17441472 2007
46
JAK-2 mutations and their relevance to myeloproliferative disease. 61 54
17133099 2007
47
Characteristic changes in platelet-large cell ratio, lactate dehydrogenase and C-reactive protein in thrombocytosis-related diseases. 54 61
17622783 2007
48
Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura. 54 61
17164950 2006
49
Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders. 61 54
17249502 2006
50
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. 61 54
16912229 2006

Variations for Thrombocytosis

Expression for Thrombocytosis

Search GEO for disease gene expression data for Thrombocytosis.

Pathways for Thrombocytosis

Pathways related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 PPBP LIF KITLG JAK2 IL6 IL3
2
Show member pathways
13.8 THPO PPBP LIF KITLG JAK2 IL6
3
Show member pathways
13.65 THPO PPBP MPL LIF JAK2 IL6
4
Show member pathways
13.51 THPO PPBP MPL KITLG JAK2 IL6
5
Show member pathways
13.41 THPO PPBP LIF KITLG JAK2 IL6
6
Show member pathways
13.35 LIF KITLG JAK2 IL6 IL3 IL1B
7
Show member pathways
13.25 THPO SERPINC1 SELP PPBP MPL JAK2
8
Show member pathways
13.21 THPO PPBP LIF KITLG JAK2 IL6
9
Show member pathways
13.05 THPO PPBP KITLG JAK2 IL6 IL3
10
Show member pathways
12.98 KITLG JAK2 IL6 IL3 EPO CSF3
11 12.85 KITLG JAK2 IL6 IL3 F2 EPO
12
Show member pathways
12.7 THPO PPBP KITLG IL6 IL3 IL1B
13 12.57 MPL KITLG JAK2 IL3 IL1B
14
Show member pathways
12.38 THPO PPBP KITLG IL6 IL3
15
Show member pathways
12.35 THPO MPL LIF JAK2 IL6 IL3
16
Show member pathways
12.34 JAK2 IL6 IL1B CSF3 CSF2
17
Show member pathways
12.31 IL6 IL1B F2 CRP
18
Show member pathways
12.26 THPO PPBP KITLG IL6 IL3 IL1B
19
Show member pathways
12.19 JAK2 IL6 IL1B IL11
20
Show member pathways
12.17 KITLG JAK2 IL3 EPO
21
Show member pathways
12.16 SERPINC1 F3 F2 CD177
22 12.11 THPO LIF KITLG IL6 IL3 IL11
23 12 LIF JAK2 IL6 IL1B
24 11.98 LIF IL6 IL1B CSF2
25 11.93 JAK2 IL6 IL1B F3
26 11.92 THPO MPL JAK2 CRP
27 11.89 IL6 IL1B IL11 CSF2
28
Show member pathways
11.88 JAK2 IL6 CSF3 CSF2
29
Show member pathways
11.8 JAK2 IL6 CRP
30 11.74 THPO PPBP KITLG IL6 IL3
31 11.73 IL6 IL1B CSF2
32 11.67 IL6 IL1B CSF3 CSF2
33 11.67 THPO MPL KITLG IL6 IL3 IL11
34
Show member pathways
11.65 IL6 IL1B CSF2
35
Show member pathways
11.62 LIF JAK2 IL6 IL11
36 11.57 LIF IL6 IL1B CSF3 CSF2
37 11.55 SELP IL6 IL1B CSF3
38 11.54 KITLG IL6 IL3 IL11 EPO
39 11.38 KITLG IL6 IL3 IL1B EPO CSF3
40 11.27 THPO KITLG IL6 IL3 IL1B IL11
41 11.26 IL6 IL3 IL1B IL11 CSF3 CSF2
42 10.97 THPO PPBP LIF KITLG IL6 IL3
43 10.77 IL6 IL1B

GO Terms for Thrombocytosis

Cellular components related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 THPO SERPINC1 PPBP LIF KITLG IL6
2 extracellular space GO:0005615 9.53 THPO SERPINC1 SELP PPBP LIF KITLG

Biological processes related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.01 SELP PPBP IL6 IL1B CRP
2 positive regulation of gene expression GO:0010628 9.99 LIF IL6 IL1B F3 CSF2 CRP
3 immune response GO:0006955 9.95 PPBP LIF IL6 IL3 IL1B CSF3
4 leukocyte migration GO:0050900 9.92 SELP IL1B F2 CD177
5 MAPK cascade GO:0000165 9.92 KITLG JAK2 IL3 IL1B CSF2
6 positive regulation of protein kinase B signaling GO:0051897 9.89 THPO KITLG F3 CSF3
7 response to lipopolysaccharide GO:0032496 9.88 SELP JAK2 IL1B EPO
8 positive regulation of MAPK cascade GO:0043410 9.86 THPO LIF IL6 IL11
9 blood coagulation GO:0007596 9.85 SERPINC1 JAK2 F3 F2 CD177
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.84 JAK2 IL6 IL1B CSF3
11 cellular response to lipopolysaccharide GO:0071222 9.83 PPBP IL6 IL1B CSF3 CSF2
12 hemostasis GO:0007599 9.78 SERPINC1 F3 F2
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 LIF IL6 IL11 CSF3
14 embryo implantation GO:0007566 9.74 LIF IL1B EPO
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 LIF JAK2 IL6 IL3 EPO CSF2
16 positive regulation of Ras protein signal transduction GO:0046579 9.72 KITLG JAK2 EPO
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 SELP JAK2 F2 EPO CSF3
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 LIF KITLG JAK2 IL6 IL3 IL11
19 myeloid cell differentiation GO:0030099 9.67 THPO TET2 CSF2
20 acute-phase response GO:0006953 9.67 IL6 F2 EPO CRP
21 cytokine-mediated signaling pathway GO:0019221 9.65 MPL LIF JAK2 IL6 IL3 IL1B
22 positive regulation of neuroinflammatory response GO:0150078 9.64 IL6 IL1B
23 negative regulation of hormone secretion GO:0046888 9.64 LIF IL11
24 negative regulation of lipid storage GO:0010888 9.63 IL6 CRP
25 tyrosine phosphorylation of STAT protein GO:0007260 9.63 LIF JAK2
26 ectopic germ cell programmed cell death GO:0035234 9.62 KITLG IL1B
27 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.6 THPO KITLG
28 thrombopoietin-mediated signaling pathway GO:0038163 9.58 THPO MPL
29 positive regulation of cell proliferation GO:0008284 9.4 THPO LIF KITLG JAK2 IL6 IL3

Molecular functions related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.65 THPO PPBP LIF KITLG IL6 IL3
2 cytokine activity GO:0005125 9.36 THPO PPBP LIF KITLG IL6 IL3

Sources for Thrombocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....